iPS Cells & Regenerative Medicine– category –
-
SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations
SelectBIO Conferences UK Overview SelectBIO Conferences will host the 'Lipid Nanoparticles (LNPs) Asia/Pacific 2026' event, focusing on LNPs, extracellular vesicles, exosomes, and Japanese research. The conference will primarily address ... -
The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges
薬事日報 Japan Overview By 2026, gene therapy is undergoing a paradigm shift, moving towards direct repair or replacement of disease-causing genes. CRISPR-based in vivo editing shows early clinical promise, pushing the vision of single-i... -
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
BioInformant USA Overview As of 2026, the iPSC-derived cell therapy pipeline shows rapid advancements in disease modeling and drug discovery, though broad clinical use in human patients still faces challenges. iPSC-derived cells hold imm... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ... -
CRISPR Therapeutics Honored with 2026 Global Recognition Award for Pioneering Gene-Editing Advances
Global Recognition Awards USA Overview CRISPR Therapeutics received the 2026 Global Recognition Award for its significant advancements in gene editing and personalized medicine. Leveraging CRISPR-Cas9 technology, the company has develope... -
NIH-Funded Breakthrough Miniaturizes CRISPR for Precision In Vivo Gene Delivery
National Institutes of Health (NIH) USA Overview An NIH-funded team has discovered and enhanced a remarkably compact CRISPR gene-editing system, Al3Cas12f, enabling precision in vivo delivery. This natural enzyme, small enough to fit wit... -
Advanced Lipid Nanoparticles Revolutionize Nucleic Acid and Gene-Editing Therapeutic Delivery
PMC (PubMed Central) USA Overview Lipid nanoparticles (LNPs) are becoming indispensable for efficient intracellular delivery of nucleic acid, mRNA, and gene-editing therapeutics, shielding them from degradation in circulation. Proven eff... -
The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy
Answers（アンサーズ） Japan Overview The global race to develop 'in vivo CAR-T therapy,' which generates CAR-T cells directly within the patient's body, is intensely accelerating as major pharmaceutical companies invest heavily. This inn... -
PMDA’s 2026 Strategy: Streamlining Approvals for Next-Gen Regenerative Medicine, Including iPSCs
独立行政法人 医薬品医療機器総合機構 (PMDA) Japan Overview Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has detailed its 2026 operational strategy for approving novel pharmaceuticals, medical devices, and regenerative medicin... -
Pioneering Pluripotency: Japan Approves World’s First iPSC-Derived Therapies for Heart Failure and Parkinson’s
再生医療 みなとみらい麻の葉クリニック Japan Overview In a historic global first, Japan's Ministry of Health, Labour and Welfare has granted conditional and time-limited approval to two induced pluripotent stem cell (iPSC)-derived regener...
